Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company posted a loss of 73 cents. As the company lacks any marketed product in its portfolio, it did not record any revenues during the quarter. Quarter in Detail In the reported quarter, general and administrative (G&A) expenses rose 40% year over year to $22.1 million. The upside was driven by an increase in the company's commercial preparation expenses in anticipation of a potential FDA approval for Kresladi gene therapy in severe leukocyte adhesion deficiency-I (LAD-I). Research and development (R&D) expenses were $45.2 million, down 2.5% from the year-ago quarter's figure. The downside was due to a decline in manufacturing and development costs. As of Mar 31, 2024, Rocket Pharmaceuticals had cash, cash equivalents and investments of $330.3 million compared with $407.5 million on Dec 31, 2023. Management expects this cash balance to fund operations and meet capital expenditure requirements into 2026. Shares of Rocket rose 2.2% in after-mar
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)Business Wire
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent ProgressBusiness Wire
RCKT
Earnings
- 5/6/24 - Beat
RCKT
Sec Filings
- 5/16/24 - Form 144
- 5/16/24 - Form 144
- 5/16/24 - Form 144
- RCKT's page on the SEC website